Loading...
Fennec Pharmaceuticals Inc.
FENC•NASDAQ
HealthcareBiotechnology
$8.43
$0.53(6.71%)
Fennec Pharmaceuticals Inc. (FENC) Stock Overview
Explore Fennec Pharmaceuticals Inc.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
123.69%
↑ 123.69%
Profit Growth
$-0.51
↑ 97.28%
EPS Growth
$-0.51
↑ 97.33%
Operating Margin
-38.76%
↑ 120.11%
ROE
589.85%
↑ 97.28%
Dividend Yield
0.00%
Analyst Recommendations
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
Price Targets
Low$15.00
Average$16.00
High$17.00
Company Profile
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
CEO
Mr. Jeffrey S. Hackman
Employees
32
Headquarters
68 TW Alexander Drive, Research Triangle Park, NC
Founded
2017